Comparing Antipsychotic Medications in LBD Over Time
Recruiting
Phase 4
Interventional Study
Parkinson's Disease Psychosis
Dementia With Lewy Bodies
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Sex
- Any
- Trial phase
- Phase 4
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 94 (estimated)
- Sponsor
- The University of Texas Health Science Center at San Antonio · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The primary objective of this study is to determine whether treatment with pimavanserin or quetiapine is associated with a greater improvement in psychosis when used in a routine clinical setting to treat hallucinations and/or delusions due to Parkinson's disease (PD) or dementia with Lewy bodies (DLB) - collectively referred to as Lewy body disease (LBD).
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Patients seen in the neurology clinic at UT Health San Antonio
* Diagnosed with psychosis due to PD or DLB
* Requiring initiation of an antipsychotic medication
* Clinical equipoise between quetiapine and pimavanserin must exist
* The prescribing provider must be comfortable p…
Contacts